Trials / Unknown
UnknownNCT05339113
Comparison of [68Ga]GaFAPI-46 PET/CT and [18F]FDG PET/CT Findings in Breast Carcinoma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- The National Center of Oncology, Azerbaijan · Other Government
- Sex
- Female
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to compare the diagnostic performance of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT in primary and metastatic lesions of breast cancer and to reveal the best diagnostic imaging time of 68Ga-FAPI-46 PET/CT.
Detailed description
Participants with breast carcinoma will undergo contemporaneous 18F-FDG and 68Ga-FAPI PET/CT. Tumor uptake will be quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG and 68Ga-FAPI PET/CT will be calculated and compared to evaluate the diagnostic efficacy. In addition, best diagnostic imaging time of 68Ga-FAPI-46 PET/CT will be evaluated at 10th, 30th and 60th minute scan time.
Conditions
- Breast Neoplasms
- Positron Emission Tomography
- Fibroblast Activation Protein Inhibitor
- Fluorodeoxyglucose F18
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 68Ga-FAPI-46 PET/CT | Patients are scanned 10 minute, 30 minute and 1 hour after 68Ga-FAPI-46 as well as one hour 18-FDG injection within 2-3 days interval. |
Timeline
- Start date
- 2021-02-04
- Primary completion
- 2022-09-01
- Completion
- 2022-12-01
- First posted
- 2022-04-21
- Last updated
- 2022-06-24
Locations
1 site across 1 country: Azerbaijan
Source: ClinicalTrials.gov record NCT05339113. Inclusion in this directory is not an endorsement.